Medication Monitor



Generic Name (Trade Name—Company)
Notes
July 1, 2019

Avatrombopag

(Doptelet—Dova Pharmaceuticals)
Avatrombopag has new indication for treatment of chronic immune thrombocytopenia

FDA approved an expanded use of avatrombopag for treatment of thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. 

Avatrombopag was previously approved for treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure.  

The drug is an oral thrombopoietin receptor agonist administered with food.

In the pivotal Phase III study, administration of avatrombopag resulted in a platelet count of at least 50,000 per µL at day eight of therapy in the majority of patients. Efficacy was superior to placebo in maintaining platelet counts in the target range during the 6-month treatment period. 

The most common adverse reactions in patients with chronic immune thrombocytopenia are headache, fatigue, contusion, epistaxis, upper respiratory tract infection, arthralgia, gingival bleeding, petechiae, and nasopharyngitis.

Full prescribing information is available at www.Dova.com.